[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 29 of about 29
1. Dadlani R, Furtado SV, Ghosal N, Prasanna KV, Hegde AS: Unusual clinical and radiological presentation of metastatic choriocarcinoma to the brain and long-term remission following emergency craniotomy and adjuvant EMA-CO chemotherapy. J Cancer Res Ther; 2010 Oct-Dec;6(4):552-6
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Unusual clinical and radiological presentation of metastatic choriocarcinoma to the brain and long-term remission following emergency craniotomy and adjuvant EMA-CO chemotherapy.
  • Choriocarcinoma is the most malignant tumor of gestational trophoblast origin.
  • Metastasis to brain is considered a poor prognostic indicator.
  • Recent advances in adjuvant radiotherapy and chemotherapy have led to an excellent outcome of these patients.
  • Craniotomy is indicated in selected cases with cerebral metastases.
  • The authors report an interesting case of an aggressive choriocarcinoma with multiple metastases to the brain and viscera.
  • The patient had radiological evidence of new lesions occurring almost every week while on the initial treatment and yet had a complete long-term remission with EMA-CO therapy.
  • The interesting presentation, radiology and adjuvant therapies are discussed.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Brain Neoplasms / pathology. Cephalometry. Choriocarcinoma / pathology
  • [MeSH-minor] Adult. Emergency Treatment. Female. Humans. Neoplasm Metastasis. Remission Induction

  • Genetic Alliance. consumer health - Choriocarcinoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] J Cancer Res Ther. 2011 Jul-Sep;7(3):383-4; author's reply 384-5 [22044835.001]
  • (PMID = 21358100.001).
  • [ISSN] 1998-4138
  • [Journal-full-title] Journal of cancer research and therapeutics
  • [ISO-abbreviation] J Cancer Res Ther
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] India
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


2. Koukourakis GV, Kouloulias V, Zacharias G, Papadimitriou C, Pantelakos P, Maravelis G, Fotineas A, Beli I, Chaldeopoulos D, Kouvaris J: Temozolomide with radiation therapy in high grade brain gliomas: pharmaceuticals considerations and efficacy; a review article. Molecules; 2009;14(4):1561-77
Hazardous Substances Data Bank. DACARBAZINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Temozolomide with radiation therapy in high grade brain gliomas: pharmaceuticals considerations and efficacy; a review article.
  • Malignant gliomas (glioblastoma multiforme and anaplastic astrocytoma) which have a combined incidence of 5-8/100,000 population, represent the most common primary central nervous system tumors.
  • The treatment outcomes even with aggressive approach including surgery, radiation therapy and chemotherapy are dismal with median reported survival is less than 1 year.
  • Temozolomide is a new drug which has shown promise in treating malignant gliomas and other difficult-to-treat tumors.
  • This drug is a per os (p.o) imidazotetrazine second-generation alkylating agent which represents the leading compound in a new class of chemotherapeutic agents that enter the cerebrospinal fluid and do not require hepatic metabolism for activation.
  • Moreover, preclinical studies have evaluated the combination of temozolomide with other alkylating agents and inhibitors of the DNA repair protein O(6)-alkylguanine alkyltransferase to overcome resistance to chemotherapy in malignant glioma and malignant metastatic melanoma.
  • At the present time temozolomide is approved in the United States for the treatment of adult patients with refractory anaplastic astrocytoma and, in the European Union, for treatment of glioblastoma multiforme showing progression or recurrence after standard therapy.
  • Temozolomide's characteristics which make it a candidate for a wide range of clinical testing to evaluate the potential of combination treatments in different tumor types are its predictable bioavailability and minimal toxicity.
  • [MeSH-major] Antineoplastic Agents, Alkylating / therapeutic use. Astrocytoma. Brain Neoplasms. Dacarbazine / analogs & derivatives. Glioblastoma
  • [MeSH-minor] Combined Modality Therapy. Drug Resistance, Neoplasm. Humans. MEDLINE. Molecular Structure. Randomized Controlled Trials as Topic

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19384285.001).
  • [ISSN] 1420-3049
  • [Journal-full-title] Molecules (Basel, Switzerland)
  • [ISO-abbreviation] Molecules
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Alkylating; 7GR28W0FJI / Dacarbazine; 85622-93-1 / temozolomide
  • [Number-of-references] 67
  •  go-up   go-down


3. Daponte A, Ascierto PA, Gravina A, Melucci M, Scala S, Ottaiano A, Simeone E, Palmieris G, Comella G: Temozolomide and cisplatin in avdanced malignant melanoma. Anticancer Res; 2005 Mar-Apr;25(2B):1441-7
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Temozolomide and cisplatin in avdanced malignant melanoma.
  • In a previous phase I study, the combination of TMZ and CDDP was tested, and the recommended dose for each drug was defined.
  • PATIENTS AND METHODS: From March 2001 to March 2002, 37 patients with metastatic melanoma, not amenable to surgery, were enrolled in this study.
  • Interferon alpha2b (IFN alpha2b) was administered at the end of chemotherapy to responsive patients at the dose of 5 M.I. U s.c.
  • 3 times a week for 1 year.
  • After chemotherapy, 9 CRs and 9 PRs were observed for an overall response rate of 48.6% (95% C.I., 31.9%-65.6%).
  • One of 5 patients with initial brain metastases showed a complete response to the therapy.
  • The median survival time was 48 weeks.
  • The schedule was well tolerated, with the most frequent adverse events reported being nausea and vomiting (59%), alopecia (14%) and fatigue (11%), all well controlled by supportive therapy.
  • Absence of recurrence in the majority (5/9; 56%) of CR patients seems to indicate that IFN may act on the duration of the response to chemotherapy.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Cisplatin / administration & dosage. Dacarbazine / administration & dosage. Dacarbazine / analogs & derivatives. Melanoma / drug therapy. Skin Neoplasms / drug therapy
  • [MeSH-minor] Adult. Aged. Disease-Free Survival. Drug Administration Schedule. Female. Humans. Interferon-alpha / administration & dosage. Male. Middle Aged. Nausea / chemically induced. Neoplasm Metastasis. Recombinant Proteins. Survival Rate. Vomiting / chemically induced

  • MedlinePlus Health Information. consumer health - Melanoma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. DACARBAZINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15865103.001).
  • [ISSN] 0250-7005
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Clinical Trial; Clinical Trial, Phase II; Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Interferon-alpha; 0 / Recombinant Proteins; 7GR28W0FJI / Dacarbazine; 85622-93-1 / temozolomide; 99210-65-8 / interferon alfa-2b; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


Advertisement
4. Delgado-López PD, Martín-Velasco V, Castilla-Díez JM, Fernández-Arconada O, Corrales-García EM, Galacho-Harnero A, Rodríguez-Salazar A, Pérez-Mies B: Metastatic meningioma to the eleventh dorsal vertebral body: total en bloc spondylectomy. Case report and review of the literature. Neurocirugia (Astur); 2006 Jun;17(3):240-9
Genetic Alliance. consumer health - Meningioma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Metastatic meningioma to the eleventh dorsal vertebral body: total en bloc spondylectomy. Case report and review of the literature.
  • To our knowledge, this is the first description of a total en bloc spondylectomy through a posterior approach for the treatment of an intraosseous metastatic meningioma to the eleventh dorsal vertebra.
  • By the end on 2003 he developed progressively invalidating dorsolumbar pain.
  • The pathological specimen was identified as adenocarcinoma and he initiated chemotherapy.
  • Workup studies failed to reveal any primary tumor.
  • In June 2004 he underwent T11 total en bloc spondylectomy (Tomita's procedure), fusion with bone and calcium substitute-filled stackable carbon-fiber cages, and T9 to L1 transpedicular screw fixation.
  • No postoperative complications ocurred and he is, so far, free from primary and secondary disease.
  • DISCUSSION: Distant metastases from intracranial meningiomas are rare entities, arising from benign lesions in, at least, 60% of cases.
  • Enam et al proposed a specific pathological score to differentiate benign, atypic and malignant meningiomas.
  • Such score correlates with the chance of metastatizing: more than 40% in malignant meningiomas compared to 3.8% of brain tumors overall.
  • Metastases ocurr more frequently in angioblastic, papillary and meningothelial variants.
  • Hematogenous (especially venous; Batson's perivertebral plexus), linfatic and cerebrospinal fluid are the main routes involved in the spreading of the tumor.
  • The interval between the onset of the intracranial disease and the appearance of the metastasis varies from months to many years.
  • [MeSH-major] Meningioma / pathology. Orthopedic Procedures / methods. Spinal Neoplasms / secondary. Spinal Neoplasms / surgery. Thoracic Vertebrae
  • [MeSH-minor] Adult. Aged. Female. Humans. Male. Middle Aged. Neoplasm Recurrence, Local. Review Literature as Topic

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16855782.001).
  • [ISSN] 1130-1473
  • [Journal-full-title] Neurocirugía (Asturias, Spain)
  • [ISO-abbreviation] Neurocirugia (Astur)
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Spain
  •  go-up   go-down


5. Whitehead RP, Moon J, McCachren SS, Hersh EM, Samlowski WE, Beck JT, Tchekmedyian NS, Sondak VK, Southwest Oncology Group: A Phase II trial of vinorelbine tartrate in patients with disseminated malignant melanoma and one prior systemic therapy: a Southwest Oncology Group study. Cancer; 2004 Apr 15;100(8):1699-704
Hazardous Substances Data Bank. VINBLASTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A Phase II trial of vinorelbine tartrate in patients with disseminated malignant melanoma and one prior systemic therapy: a Southwest Oncology Group study.
  • BACKGROUND: Single-agent chemotherapy with dacarbazine continues to be the standard of care for the treatment of metastatic melanoma.
  • However, there is a large population of patients who have failed first-line therapy and might benefit from additional treatment.
  • In the current study, the authors evaluated the antitumor effects and toxicity of vinorelbine therapy in patients who had failed one prior systemic therapy.
  • METHODS: Patients were required to have a histologic diagnosis of melanoma and be of Stage IV with measurable disease, a Southwest Oncology Group (SWOG) performance status (PS) of 0-2, no evidence of brain metastases, and adequate bone marrow and liver function.
  • Treatment was comprised of vinorelbine given at a dose of 30 mg/m(2)/week by intravenous bolus.
  • The group of previously treated patients may be used to evaluate new agents for the treatment of disseminated melanoma.
  • [MeSH-major] Antineoplastic Agents, Phytogenic / therapeutic use. Melanoma / drug therapy. Skin Neoplasms / drug therapy. Vinblastine / analogs & derivatives. Vinblastine / therapeutic use
  • [MeSH-minor] Adult. Aged. Disease-Free Survival. Drug Resistance, Neoplasm. Female. Humans. Injections, Intravenous. Male. Middle Aged. Neoplasm Metastasis

  • MedlinePlus Health Information. consumer health - Melanoma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. VINORELBINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2004 American Cancer Society.
  • (PMID = 15073859.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA13612; United States / NCI NIH HHS / CA / CA20319; United States / NCI NIH HHS / CA / CA22433; United States / NCI NIH HHS / CA / CA32102; United States / NCI NIH HHS / CA / CA35176; United States / NCI NIH HHS / CA / CA35431; United States / NCI NIH HHS / CA / CA37981; United States / NCI NIH HHS / CA / CA38926; United States / NCI NIH HHS / CA / CA42777; United States / NCI NIH HHS / CA / CA45807; United States / NCI NIH HHS / CA / CA46441; United States / NCI NIH HHS / CA / CA58348; United States / NCI NIH HHS / CA / CA58861; United States / NCI NIH HHS / CA / CA63850; United States / NCI NIH HHS / CA / CA67575; United States / NCI NIH HHS / CA / CA76132
  • [Publication-type] Clinical Trial; Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Phytogenic; 5V9KLZ54CY / Vinblastine; Q6C979R91Y / vinorelbine
  •  go-up   go-down


6. Hwu WJ, Lis E, Menell JH, Panageas KS, Lamb LA, Merrell J, Williams LJ, Krown SE, Chapman PB, Livingston PO, Wolchok JD, Houghton AN: Temozolomide plus thalidomide in patients with brain metastases from melanoma: a phase II study. Cancer; 2005 Jun 15;103(12):2590-7
Hazardous Substances Data Bank. THALIDOMIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Temozolomide plus thalidomide in patients with brain metastases from melanoma: a phase II study.
  • BACKGROUND: Temozolomide plus thalidomide is a promising oral combination regimen for the treatment of metastatic melanoma.
  • The current Phase II study examined the efficacy and safety of this combination in chemotherapy-naive patients with brain metastases.
  • METHODS: Patients with histologically confirmed metastatic melanoma and measurable brain metastases received temozolomide (75 mg/m2 per day for 6 weeks with a 2-week break between cycles) plus concomitant thalidomide (200 mg/day escalating to 400 mg/day for patients < 70 years or 100 mg/day escalating to 250 mg/day for patients > or = 70 years).
  • The primary end point was tumor response in the brain assessed every 8 weeks.
  • All patients had progressive brain metastases: 16 were symptomatic and 25 had extensive extracranial metastases.
  • Eight patients had received whole-brain radiotherapy, 4 had received stereotactic radiotherapy, and 8 had received craniotomy with resection of hemorrhagic lesions.
  • Fifteen patients completed > or = 1 cycle (median, 1 cycle; range, 0-4 cycles), and 11 discontinued treatment before completing 1 cycle (7 for intracranial hemorrhage, 2 for pulmonary embolism, 1 for deep vein thrombosis, and 1 for Grade 3 rash).
  • Of 15 patients assessable for response, 3 had a complete or partial response (12% intent to treat) and 7 had minor response or stable disease in the brain.
  • CONCLUSIONS: Temozolomide plus thalidomide was an active oral regimen for patients with brain metastases from malignant melanoma.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Brain Neoplasms / drug therapy. Dacarbazine / analogs & derivatives. Melanoma / drug therapy. Skin Neoplasms / drug therapy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Disease-Free Survival. Female. Humans. Male. Middle Aged. Neoplasm Staging. Survival Rate. Thalidomide / administration & dosage. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Melanoma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. DACARBAZINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2005 American Cancer Society.
  • (PMID = 15861414.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Clinical Trial; Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 4Z8R6ORS6L / Thalidomide; 7GR28W0FJI / Dacarbazine; 85622-93-1 / temozolomide
  •  go-up   go-down


7. Chen W: Clinical applications of PET in brain tumors. J Nucl Med; 2007 Sep;48(9):1468-81
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical applications of PET in brain tumors.
  • Malignant gliomas and metastatic tumors are the most common brain tumors.
  • In high-grade and metastatic tumors, the imaging challenge is to distinguish between recurrent tumor and treatment-induced changes such as radiation necrosis.
  • The current clinical gold standard, MRI, provides superior structural detail but poor specificity in identifying viable tumors in brain treated with surgery, radiation, or chemotherapy. (18)F-FDG PET identifies anaplastic transformation and has prognostic value.
  • The sensitivity and specificity of (18)F-FDG in evaluating recurrent tumor and treatment-induced changes can be improved significantly by co-registration with MRI and potentially by delayed imaging 3-8 h after injection.
  • They are also promising in differentiating between recurrent tumors and treatment-induced changes.
  • [MeSH-major] Brain Neoplasms / radionuclide imaging. Fluorodeoxyglucose F18. Glioma / radionuclide imaging. Radiopharmaceuticals
  • [MeSH-minor] Adult. Amino Acids. Biopsy / methods. Female. Humans. Magnetic Resonance Imaging. Male. Middle Aged. Neoplasm Metastasis. Neoplasm Recurrence, Local. Positron-Emission Tomography

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17704239.001).
  • [ISSN] 0161-5505
  • [Journal-full-title] Journal of nuclear medicine : official publication, Society of Nuclear Medicine
  • [ISO-abbreviation] J. Nucl. Med.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / P50 CA 086306
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, Non-P.H.S.; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Amino Acids; 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18
  • [Number-of-references] 109
  •  go-up   go-down


8. Thongprasert S, Cheewakriangkrai R, Napapan S: Docetaxel as second-line chemotherapy for advanced non-small cell lung cancer. J Med Assoc Thai; 2002 Dec;85(12):1296-300
Hazardous Substances Data Bank. TAXOL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Docetaxel as second-line chemotherapy for advanced non-small cell lung cancer.
  • The purpose of this study was to evaluate the efficacy and safety of docetaxel as second-line chemotherapy for advanced non-small cell lung cancer (NSCLC).
  • Five cases (19.2%) had liver metastases, 3 (11.5%) brain metastases, 6 (23%) bone metastases, and 17 (65.3%) metastatic nodules in the lung.
  • Besides chemotherapy, seven cases had received prior thoracic irradiation and two whole brain irradiation.
  • Two cases had prior surgery for malignant pleural effusion and one had thoracotomy for the resection of the primary tumor.
  • The time from the last dose of chemotherapy to the start of this study was less than 6 months in 20 cases, 6-12 months in 9, 12-24 months in 3 and more than 24 months in 2 cases.
  • One patient with initial small cell lung cancer had developed NSCLC before entering this study.
  • The median survival time was 23.8 weeks.
  • Docetaxel should be considered as second line chemotherapy in advanced NSCLC when primary chemotherapy including cisplatin and/or paclitaxel had failed.
  • [MeSH-major] Carcinoma, Non-Small-Cell Lung / drug therapy. Carcinoma, Non-Small-Cell Lung / pathology. Lung Neoplasms / drug therapy. Lung Neoplasms / pathology. Paclitaxel / administration & dosage. Paclitaxel / analogs & derivatives. Palliative Care / methods. Taxoids
  • [MeSH-minor] Adult. Aged. Dose-Response Relationship, Drug. Drug Administration Schedule. Female. Follow-Up Studies. Humans. Infusions, Intravenous. Male. Middle Aged. Neoplasm Staging. Survival Analysis. Treatment Outcome

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Non-small cell lung cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Palliative Care.
  • Hazardous Substances Data Bank. DOCETAXEL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12678167.001).
  • [ISSN] 0125-2208
  • [Journal-full-title] Journal of the Medical Association of Thailand = Chotmaihet thangphaet
  • [ISO-abbreviation] J Med Assoc Thai
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] Thailand
  • [Chemical-registry-number] 0 / Taxoids; 15H5577CQD / docetaxel; P88XT4IS4D / Paclitaxel
  •  go-up   go-down


9. Masucci GV, Månsson-Brahme E, Ragnarsson-Olding B, Nilsson B, Wagenius G, Hansson J: Alternating chemo-immunotherapy with temozolomide and low-dose interleukin-2 in patients with metastatic melanoma. Melanoma Res; 2006 Aug;16(4):357-63
Hazardous Substances Data Bank. DACARBAZINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Alternating chemo-immunotherapy with temozolomide and low-dose interleukin-2 in patients with metastatic melanoma.
  • Previous clinical trials suggested that temozolomide in sequence with low-dose recombinant human interleukin-2 might be an efficacious and relatively non-toxic chemo-immunotherapeutic treatment, which may synergistically eliminate tumours.
  • The primary objective was to determine the safety and tolerance of temozolomide administered orally 200 mg/m days 1-5, in sequential combination with subcutaneous injections of 4.5x10 IU recombinant human interleukin-2 on days 8-11, 15-18 and 22-25 in patients with measurable, progressive metastatic malignant melanoma without radiological signs of central nervous system metastases.
  • The secondary objectives were to determine tumour response and time to progression.
  • Three patients suspended the treatment because of WHO grade 3 side effects already during the first 3 days of the first course of temozolomide.
  • Seven patients showed no tumour progression during the first four treatment cycles.
  • Two patients had complete responses, three partial responses and two stable disease at the end of the four cycles defined by the protocol and they continued the treatment until signs of relapse or a maximum of 21 courses.
  • Thrombocytopenia was significantly more pronounced in patients with objective response and stable disease than in non-responders to therapy.
  • The median time to progression for all patients was 3.1 months and for responding and stable disease patients was 15 months.
  • Five of 23 treated patients (22%) developed brain metastases during follow-up.
  • Temozolomide in combination with recombinant human interleukin-2 is a well-tolerated regimen for outpatient treatment and the bio-chemotherapy combination induced durable clinical responses.
  • Thrombocytopenia might be a positive predictive factor for response to therapy.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Kidney Neoplasms / drug therapy. Liver Neoplasms / drug therapy. Lung Neoplasms / drug therapy. Melanoma / drug therapy
  • [MeSH-minor] Administration, Oral. Adult. Aged. Dacarbazine / administration & dosage. Dacarbazine / analogs & derivatives. Female. Humans. Immunotherapy. Injections, Subcutaneous. Interleukin-2 / administration & dosage. Lymphatic Metastasis / immunology. Lymphatic Metastasis / pathology. Male. Maximum Tolerated Dose. Middle Aged. Neoplasm Staging. Skin Neoplasms / drug therapy. Skin Neoplasms / immunology. Skin Neoplasms / pathology. Survival Rate

  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Melanoma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16845332.001).
  • [ISSN] 0960-8931
  • [Journal-full-title] Melanoma research
  • [ISO-abbreviation] Melanoma Res.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Interleukin-2; 7GR28W0FJI / Dacarbazine; 85622-93-1 / temozolomide
  •  go-up   go-down


10. Lutterbach J, Spetzger U, Bartelt S, Pagenstecher A: Malignant germ cell tumors metastatic to the brain: a model for a curable neoplasm? The Freiburg experience and a review of the literature. J Neurooncol; 2002 Jun;58(2):147-56
MedlinePlus Health Information. consumer health - Testicular Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Malignant germ cell tumors metastatic to the brain: a model for a curable neoplasm? The Freiburg experience and a review of the literature.
  • The aim of this study on malignant germ cell tumors metastasizing to the brain is (a) to report our institutional experience, (b) to present three patients surviving for more than seven years, and (c) to review the literature with regard to long-term survival.
  • From 1985 to 2000, 916 consecutive patients were treated with whole brain radiation therapy for brain metastases at our hospital.
  • Eleven patients had cerebral lesions from histologically proven malignant germ cell tumors.
  • Brain metastases were diagnosed at presentation (n = 2), following complete remission (n = 3), or along with extracerebral tumor progression (n = 6).
  • Seven patients had a single brain metastasis.
  • Eight patients reached the planned total dose of 50 Gy.
  • Eight patients had chemotherapy.
  • The long-term survivors all had an isolated cerebral relapse after complete remission, presented with a single brain metastasis, and were treated with resection and whole brain radiation therapy to a total dose of 50 Gy.
  • The first patient died from a late relapse 89 months after the diagnosis of brain metastasis, the second patient is well and alive at 95 months.
  • He is alive at 194 months, the longest survival for brain metastases from malignant germ cell tumors ever reported.
  • Resection and whole brain radiation therapy might result in durable cerebral control with minimal morbidity.
  • [MeSH-major] Brain Neoplasms / secondary. Germinoma / secondary. Testicular Neoplasms / pathology
  • [MeSH-minor] Adolescent. Adult. Combined Modality Therapy. Humans. Male. Middle Aged. Survival Analysis

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Br Med J. 1979 Jan 27;1(6158):233-4 [421046.001]
  • [Cites] Int J Urol. 1997 Sep;4(5):527-9 [9354961.001]
  • [Cites] J Clin Oncol. 1997 Feb;15(2):594-603 [9053482.001]
  • [Cites] Cancer. 1980 Sep 15;46(6):1339-44 [6158370.001]
  • [Cites] J Clin Oncol. 1994 Mar;12(3):627-42 [8120563.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2000 Jan 15;46(2):297-302 [10661335.001]
  • [Cites] Med Oncol. 2000 Nov;17(4):279-86 [11114706.001]
  • [Cites] Urologe A. 1998 Nov;37(6):635-47 [9887493.001]
  • [Cites] Med Pediatr Oncol. 1992;20(1):68-70 [1370071.001]
  • [Cites] Oncol Rep. 2001 Mar-Apr;8(2):219-23 [11182030.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1994 Jul 1;29(4):711-7 [8040016.001]
  • [Cites] J Clin Oncol. 1997 Apr;15(4):1449-54 [9193339.001]
  • [Cites] N Engl J Med. 1987 Jun 4;316(23):1435-40 [2437455.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2001 Oct 1;51(2):426-34 [11567817.001]
  • [Cites] Cancer. 1986 Jun 1;57(11):2108-13 [2421864.001]
  • [Cites] Cancer. 1981 Mar 1;47(5):978-81 [7194730.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1992;22(1):17-22 [1370066.001]
  • [Cites] Br J Urol. 1987 Oct;60(4):364-7 [2825897.001]
  • [Cites] Clin Exp Metastasis. 1994 May;12(3):226-30 [8194197.001]
  • [Cites] Br J Cancer. 1979 Mar;39(3):217-23 [88952.001]
  • [Cites] BJU Int. 1999 Mar;83(4):457-61 [10210571.001]
  • [Cites] Clin Cancer Res. 1997 Dec;3(12 Pt 2):2630-2 [10068265.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1997 Mar 1;37(4):745-51 [9128946.001]
  • [Cites] Ann Oncol. 1997 May;8(5):477-83 [9233528.001]
  • [Cites] Cancer. 1983 Nov 1;52(9):1728-35 [6684500.001]
  • [Cites] Ital J Neurol Sci. 1997 Jun;18(3):173-5 [9241566.001]
  • [Cites] Neurosurgery. 1989 Nov;25(5):814-9 [2555732.001]
  • [Cites] Cancer. 1982 Jan 1;49(1):12-8 [6274499.001]
  • [Cites] J Clin Oncol. 1984 Dec;2(12):1397-403 [6210350.001]
  • [Cites] Cancer. 1979 Dec;44(6):2349-53 [228844.001]
  • [Cites] Cancer. 1999 Feb 15;85(4):988-97 [10091779.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1998 Aug 1;42(1):155-9 [9747833.001]
  • [Cites] N Engl J Med. 1990 Feb 22;322(8):494-500 [2405271.001]
  • [Cites] Neurol Med Chir (Tokyo). 1991 May;31(5):277-82 [1717863.001]
  • [Cites] J Natl Cancer Inst. 2000 Jul 19;92(14):1165-71 [10904090.001]
  • (PMID = 12164687.001).
  • [ISSN] 0167-594X
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 37
  •  go-up   go-down


11. Gudena V, Verma N, Post G, Kizziah M, Fenning R, Montero AJ: Metastatic chest wall malignant schwannoma responding to sorafenib: case report and literature review. Cancer Biol Ther; 2008 Jun;7(6):810-3
Hazardous Substances Data Bank. NICOTINAMIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Metastatic chest wall malignant schwannoma responding to sorafenib: case report and literature review.
  • Malignant schwannomas or malignant peripheral nerve sheath tumors (MPNST) represent approximately 10% of all soft tissue sarcomas.
  • Metastatic disease from chest wall MPNST is very rare.
  • We present a case of a major clinical response to the tyrosine kinase inhibitor (TKI) sorafenib in a patient with metastatic MPNST.
  • A 42-year-old female with a prior history of neurofibromas developed MPNST, which later metastasized to the lungs and brain.
  • She was initially placed on sorafenib with significant clinical response to lung metastases.
  • Studies are ongoing and the results are eagerly awaited regarding the responses to these medications and whether they can positively impact on the natural history of this disease.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Benzenesulfonates / therapeutic use. Nerve Sheath Neoplasms / diagnosis. Nerve Sheath Neoplasms / drug therapy. Neurilemmoma / diagnosis. Neurilemmoma / drug therapy. Pyridines / therapeutic use. Thoracic Wall / pathology
  • [MeSH-minor] Adult. Brain Neoplasms / drug therapy. Brain Neoplasms / secondary. Female. Humans. Lung Neoplasms / drug therapy. Lung Neoplasms / secondary. Magnetic Resonance Imaging. Neoplasm Metastasis. Niacinamide / analogs & derivatives. Phenylurea Compounds. Protein Kinase Inhibitors / therapeutic use. Radiography, Thoracic. Treatment Outcome

  • Genetic Alliance. consumer health - Schwannoma.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18376142.001).
  • [ISSN] 1555-8576
  • [Journal-full-title] Cancer biology & therapy
  • [ISO-abbreviation] Cancer Biol. Ther.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Benzenesulfonates; 0 / Phenylurea Compounds; 0 / Protein Kinase Inhibitors; 0 / Pyridines; 25X51I8RD4 / Niacinamide; 9ZOQ3TZI87 / sorafenib
  •  go-up   go-down


12. Talton CC, Hopkins JO, Walley BD, Kincaid EH: Metastatic thymic carcinoid: a case report. Am Surg; 2005 Jul;71(7):578-80
MedlinePlus Health Information. consumer health - Thymus Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Metastatic thymic carcinoid: a case report.
  • They have malignant potential, the capacity for distant metastasis, and often present with associated endocrinopathies.
  • This report describes a patient who was diagnosed with thymic carcinoid and Cushing syndrome at age 19 that, despite complete surgical excision of his tumor, developed local recurrence with distant metastases to his brain, lungs, and bone.
  • We discuss the evolution of this patient's illness as well as the therapies used in his care.
  • We also discuss the role of adjuvant therapy, which in our case consisted of chemotherapy, radiotherapy, and several new therapies including an antiangiogenesis agent and a tyrosine kinase inhibitor.
  • [MeSH-major] Carcinoma, Neuroendocrine / secondary. Carcinoma, Neuroendocrine / surgery. Neoplasm Recurrence, Local / pathology. Neoplasms, Multiple Primary / pathology. Palliative Care / methods. Thymus Neoplasms / pathology
  • [MeSH-minor] Adult. Biopsy, Needle. Bone Neoplasms / secondary. Bone Neoplasms / therapy. Brain Neoplasms / secondary. Brain Neoplasms / therapy. Disease Progression. Fatal Outcome. Humans. Immunohistochemistry. Lung Neoplasms / secondary. Lung Neoplasms / therapy. Male. Neoplasm Staging. Thymectomy / methods

  • MedlinePlus Health Information. consumer health - Palliative Care.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16089122.001).
  • [ISSN] 0003-1348
  • [Journal-full-title] The American surgeon
  • [ISO-abbreviation] Am Surg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


13. Poelen J, Bernsen HJ, Prick MJ: Metastatic medulloblastoma in an adult; treatment with temozolomide. Acta Neurol Belg; 2007 Jun;107(2):51-4
Hazardous Substances Data Bank. DACARBAZINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Metastatic medulloblastoma in an adult; treatment with temozolomide.
  • Medulloblastoma is a malignant brain tumour most frequently seen in children.
  • Treatment of this tumour type usually consists of surgery followed by radiotherapy.
  • Relapses of medulloblastoma are sensitive to chemotherapy and treatment with chemotherapeutics in children has increased the survival rates.
  • A medulloblastoma at adult age is extremely rare, and there is no overall accepted treatment, especially not in the case of a relapse.
  • This observation encouraged us to decide to treat an adult patient with a recurrent medulloblastoma with temozolomide.
  • This female patient showed a recurrence of a medulloblastoma 7 years after the initial presentation with metastatic spread along the neuraxis and progressive neurological deterioration.
  • Treatment with temozolomide resulted in relief of clinical symptoms and stabilization of tumour growth for 8 months.
  • [MeSH-major] Antineoplastic Agents, Alkylating / therapeutic use. Cerebellar Neoplasms / drug therapy. Dacarbazine / analogs & derivatives. Medulloblastoma / drug therapy. Neoplasm Recurrence, Local / drug therapy
  • [MeSH-minor] Adult. Female. Humans. Magnetic Resonance Imaging. Spinal Cord Neoplasms / drug therapy. Spinal Cord Neoplasms / secondary

  • Genetic Alliance. consumer health - Medulloblastoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17710841.001).
  • [ISSN] 0300-9009
  • [Journal-full-title] Acta neurologica Belgica
  • [ISO-abbreviation] Acta Neurol Belg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Belgium
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Alkylating; 7GR28W0FJI / Dacarbazine; 85622-93-1 / temozolomide
  •  go-up   go-down


14. Reardon DA, Akabani G, Coleman RE, Friedman AH, Friedman HS, Herndon JE 2nd, McLendon RE, Pegram CN, Provenzale JM, Quinn JA, Rich JN, Vredenburgh JJ, Desjardins A, Gururangan S, Badruddoja M, Dowell JM, Wong TZ, Zhao XG, Zalutsky MR, Bigner DD: Salvage radioimmunotherapy with murine iodine-131-labeled antitenascin monoclonal antibody 81C6 for patients with recurrent primary and metastatic malignant brain tumors: phase II study results. J Clin Oncol; 2006 Jan 1;24(1):115-22
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Salvage radioimmunotherapy with murine iodine-131-labeled antitenascin monoclonal antibody 81C6 for patients with recurrent primary and metastatic malignant brain tumors: phase II study results.
  • PURPOSE: To assess the efficacy and toxicity of intraresection cavity iodine-131-labeled murine antitenascin monoclonal antibody 81C6 (131I-m81C6) among recurrent malignant brain tumor patients.
  • PATIENTS AND METHODS: In this phase II trial, 100 mCi of 131I-m81C6 was injected directly into the surgically created resection cavity (SCRC) of 43 patients with recurrent malignant glioma (glioblastoma multiforme [GBM], n = 33; anaplastic astrocytoma [AA], n = 6; anaplastic oligodendroglioma [AO], n = 2; gliosarcoma [GS], n = 1; and metastatic adenocarcinoma, n = 1) followed by chemotherapy.
  • Ten patients (23%) developed acute hematologic toxicity.
  • Five patients (12%) developed acute reversible neurotoxicity.
  • One patient (2%) developed irreversible neurotoxicity.
  • CONCLUSION: In this single-institution phase II study, administration of 100 mCi of 131I-m81C6 to recurrent malignant glioma patients followed by chemotherapy is associated with a median survival that is greater than that of historical controls treated with surgery plus iodine-125 brachytherapy.
  • We are now conducting a phase II trial, approved by the US Food and Drug Administration, using patient-specific 131I-m81C6 dosing, to deliver 44 Gy to the SCRC followed by standardized chemotherapy.
  • [MeSH-major] Antibodies, Monoclonal / therapeutic use. Brain Neoplasms / radiotherapy. Iodine Radioisotopes / therapeutic use. Neoplasm Recurrence, Local / radiotherapy. Radioimmunotherapy. Tenascin / immunology
  • [MeSH-minor] Adult. Aged. Biopsy. Female. Humans. Male. Middle Aged. Neoplasm Metastasis. Salvage Therapy

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] J Clin Oncol. 2006 Mar 20;24(9):1484. Guruangan, Sri [corrected to Gururangan, Sridharan]
  • (PMID = 16382120.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / 1-P50-CA108786-01; United States / NCI NIH HHS / CA / CA11898; United States / NCRR NIH HHS / RR / MO1 RR 30; United States / NINDS NIH HHS / NS / NS20023
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Iodine Radioisotopes; 0 / Tenascin
  •  go-up   go-down


15. Gupta D, Neto AG, Deavers MT, Silva EG, Malpica A: Metastatic melanoma to the vagina: clinicopathologic and immunohistochemical study of three cases and literature review. Int J Gynecol Pathol; 2003 Apr;22(2):136-40
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Metastatic melanoma to the vagina: clinicopathologic and immunohistochemical study of three cases and literature review.
  • We report the clinicopathologic features of three cases of malignant melanoma metastatic to the vagina; only one similar case has been previously reported.
  • Two patients had a history of a previous primary malignant melanoma, one a preauricular melanoma treated 7 years earlier and the other a vulvar melanoma treated 2 years earlier.
  • In the third case, a primary malignant melanoma was found on the sole of the right foot after the patient had presented with the vaginal metastases.
  • All were of epithelioid cell type and were positive with S-100 and microphthalmia-transcription factor.
  • One patient underwent wide local excision of tumor followed by chemotherapy, one patient had intracavitary radiotherapy, and one had palliative radiotherapy to the brain only.
  • [MeSH-major] Biomarkers, Tumor / analysis. Melanoma / secondary. Skin Neoplasms / pathology. Vaginal Neoplasms / secondary
  • [MeSH-minor] Adult. Aged. Antigens, Neoplasm. DNA-Binding Proteins / metabolism. Fatal Outcome. Female. Humans. Immunohistochemistry. MART-1 Antigen. Melanoma-Specific Antigens. Microphthalmia-Associated Transcription Factor. Monophenol Monooxygenase / metabolism. Neoplasm Proteins / metabolism. Retrospective Studies. S100 Proteins / metabolism. Transcription Factors / metabolism

  • MedlinePlus Health Information. consumer health - Melanoma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • MedlinePlus Health Information. consumer health - Vaginal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12649667.001).
  • [ISSN] 0277-1691
  • [Journal-full-title] International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists
  • [ISO-abbreviation] Int. J. Gynecol. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / Biomarkers, Tumor; 0 / DNA-Binding Proteins; 0 / MART-1 Antigen; 0 / MITF protein, human; 0 / MLANA protein, human; 0 / Melanoma-Specific Antigens; 0 / Microphthalmia-Associated Transcription Factor; 0 / Neoplasm Proteins; 0 / S100 Proteins; 0 / Transcription Factors; EC 1.14.18.1 / Monophenol Monooxygenase
  •  go-up   go-down


16. Konstadoulakis MM, Messaris E, Zografos G, Androulakis G, Karakousis C: Prognostic factors in malignant melanoma patients with solitary or multiple brain metastases. Is there a role for surgery? J Neurosurg Sci; 2000 Dec;44(4):211-8; discussion 219
MedlinePlus Health Information. consumer health - Melanoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic factors in malignant melanoma patients with solitary or multiple brain metastases. Is there a role for surgery?
  • BACKGROUND: The aim of this study is to evaluate the prognostic parameters and treatment modalities of malignant melanoma patients with brain metastases.
  • PATIENTS: the charts of 136 patients, treated in Roswell Park Cancer Institute, for melanoma brain metastases, were analyzed.
  • INTERVENTIONS: all patients were treated surgically and in the majority adjuvant therapy was applied.
  • MEASURES: survival and time of recurrence of patients and possible prognostic factors.
  • RESULTS: PATIENTS who were treated surgically had a better one-year survival rate (28.3%), than patients who received radiotherapy and/or chemotherapy (6.67%) or patients who refused any kind of treatment (3.45%), (p=0.006).
  • Prolonged survival after surgical treatment was found in patients with single metastatic lesions and in patients with multiple metastatic lesions.
  • CONCLUSIONS: Melanoma patients with single metastatic lesions to the brain seem to do better after surgical treatment.
  • The role of surgical intervention in patients with multiple brain metastases needs re-evaluation from a big multicenter, prospective trial.
  • [MeSH-major] Brain Neoplasms / secondary. Brain Neoplasms / surgery. Melanoma / secondary. Melanoma / surgery
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Antineoplastic Agents / therapeutic use. Chemotherapy, Adjuvant. Combined Modality Therapy. Female. Follow-Up Studies. Head and Neck Neoplasms / mortality. Head and Neck Neoplasms / pathology. Head and Neck Neoplasms / secondary. Head and Neck Neoplasms / surgery. Humans. Male. Middle Aged. Neoplasm Staging. Prognosis. Retrospective Studies. Survival Rate. Time Factors

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11327290.001).
  • [ISSN] 0390-5616
  • [Journal-full-title] Journal of neurosurgical sciences
  • [ISO-abbreviation] J Neurosurg Sci
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


17. Lewis KD, Gibbs P, O'Day S, Richards J, Weber J, Anderson C, Zeng C, Baron A, Russ P, Gonzalez R: A phase II study of biochemotherapy for advanced melanoma incorporating temozolomide, decrescendo interleukin-2 and GM-CSF. Cancer Invest; 2005;23(4):303-8
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Metastatic malignant melanoma remains a very difficult disease to treat.
  • Previous phase II studies using biochemotherapy (combination of platinum-containing chemotherapy with IL-2 and IFNalpha) have shown response rates of about 50%.
  • We report the results of a phase II study using a novel biochemotherapy regimen containing temozolomide, cisplatin, decrescendo IL-2, IFNalpha, and GM-CSF in the treatment of stage IV melanoma.
  • Seventy-one patients with histologically confirmed metastatic melanoma were enrolled between June 1998 and October 1999.
  • Prior chemotherapy or IL-2 was not permitted.
  • Twenty-one patients (30%) had a history of treated brain metastases.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Melanoma / drug therapy
  • [MeSH-minor] Adult. Aged. Antineoplastic Agents, Alkylating / administration & dosage. Brain Neoplasms / mortality. Brain Neoplasms / secondary. Dacarbazine / administration & dosage. Dacarbazine / analogs & derivatives. Eye Neoplasms / drug therapy. Eye Neoplasms / mortality. Eye Neoplasms / pathology. Granulocyte-Macrophage Colony-Stimulating Factor / administration & dosage. Humans. Interleukin-2 / administration & dosage. Middle Aged. Neoplasm Metastasis. Reproducibility of Results. Skin Neoplasms / drug therapy. Skin Neoplasms / mortality. Skin Neoplasms / pathology. Survival Analysis

  • MedlinePlus Health Information. consumer health - Melanoma.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. DACARBAZINE .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16100942.001).
  • [ISSN] 0735-7907
  • [Journal-full-title] Cancer investigation
  • [ISO-abbreviation] Cancer Invest.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / P30 CA46934
  • [Publication-type] Clinical Trial; Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Alkylating; 0 / Interleukin-2; 7GR28W0FJI / Dacarbazine; 83869-56-1 / Granulocyte-Macrophage Colony-Stimulating Factor; 85622-93-1 / temozolomide
  •  go-up   go-down


18. Rock JP, Scarpace L, Hearshen D, Gutierrez J, Fisher JL, Rosenblum M, Mikkelsen T: Associations among magnetic resonance spectroscopy, apparent diffusion coefficients, and image-guided histopathology with special attention to radiation necrosis. Neurosurgery; 2004 May;54(5):1111-7; discussion 1117-9
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: In patients with malignant glioma previously treated with surgery, radiation, and chemotherapy, clinical and radiographic signs of recurrent disease often require differentiation between radiation necrosis and recurrent tumor.
  • Published work suggests that although magnetic resonance spectroscopy (MRS) can reliably differentiate pure tumor, pure necrosis, and spectroscopically normal tissues, it may not be particularly helpful because most patients have mixed histological findings comprised of necrosis and tumor.
  • Spectral data for pure tumor, pure necrosis, and mixed tumor and necrosis were derived from 65 spectroscopic observations in patients with previously treated gliomas (n = 16) and metastatic tumors (n = 2).
  • Spectral data for choline (Cho), N-acetylaspartate (NAA), creatine (Cr), and lipid-lactate were analyzed separately and in conjunction with ADCs in all patients (15 observations of pure tumor, 33 observations of pure necrosis, and 13 observations of mixed tumor and necrosis).
  • Histological specimens were obtained stereotactically at the time of surgery (<48 h after image acquisition) for recurrent disease and digitally co-registered with MRS data.
  • RESULTS: ADC values for pure tumor, pure necrosis, and mixed tumor and necrosis were 1.30, 1.60, and 1.42, respectively.
  • Cho/NAA less than 0.20, NAA/normal Cr greater than 1.56, and NAA/Cho greater than 1.32 increase the odds that a tissue biopsy will be pure necrosis versus mixed tumor and necrosis.
  • Although various values of all MRS ratios analyzed may provide positive correlations for histopathological differentiation of tissue between that of pure tumor and that of pure necrosis, the addition of ADC values to only NAA/Cho and NAA/normal Cr increases the odds of correct differentiation between pure tumor and pure necrosis.
  • The addition of ADC values does not provide additional information beyond that of MRS in distinguishing specimens of mixed tumor and necrosis from either pure tumor or pure necrosis.
  • CONCLUSION: It has been demonstrated that MRS ratio analysis may allow for the clinical discrimination between specimens of pure tumor and pure necrosis, and the addition of ADC data into this analysis may enhance this specific differentiation.
  • However, although a trend toward correlation between ADC values and the various histopathological features was noted, the direct addition of ADC data does not seem to allow further discrimination, beyond that provided by MRS, among specimens of mixed tumor and necrosis and either pure tumor or pure necrosis.
  • [MeSH-major] Brain / pathology. Brain Neoplasms / diagnosis. Diffusion Magnetic Resonance Imaging. Magnetic Resonance Spectroscopy. Neoplasm Recurrence, Local / diagnosis. Radiation Injuries / diagnosis
  • [MeSH-minor] Adult. Diagnosis, Differential. Humans. Necrosis

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15113465.001).
  • [ISSN] 0148-396X
  • [Journal-full-title] Neurosurgery
  • [ISO-abbreviation] Neurosurgery
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


19. Mimeault M, Batra SK: Targeting of cancer stem/progenitor cells plus stem cell-based therapies: the ultimate hope for treating and curing aggressive and recurrent cancers. Panminerva Med; 2008 Mar;50(1):3-18
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Targeting of cancer stem/progenitor cells plus stem cell-based therapies: the ultimate hope for treating and curing aggressive and recurrent cancers.
  • The rapid progression from aggressive primary cancers into locally advanced and invasive and/or metastatic diseases remains a big obstacle for an early diagnosis and curative therapeutic intervention for cancer patients.
  • The late-stage leukemias and disseminated and metastatic sarcomas, melanomas, brain tumors and epithelial cancers are the devastating diseases associated with a high rate of recurrence after treatment with the conventional clinical therapies including surgery, ionizing radiation, hormonal therapy and systemic chemotherapy, which generally lead to the death of patients.
  • Therefore, the establishment of the molecular events underlying cancer initiation and progression into locally invasive and metastatic diseases is of major interest in basic cancer research as well as for the development of new effective clinical therapeutic options against the recurrent and lethal cancers.
  • Recent advances have led to the identification of specific oncogenic products that are implicated in the malignant transformation of adult stem/progenitor cells into leukemic or tumorigenic and migrating cancer stem/progenitor cells during cancer progression.
  • Of therapeutic interest, the molecular targeting of deregulated signaling elements in cancer stem/progenitor cells and their local microenvironment represents a new potential strategy for the development of more effective clinical treatments against aggressive cancers.
  • Particularly, the combined use of chemotherapeutic drugs to eradicate cancer-initiating cells with hematopoietic stem cell or genetically-modified stem cell transplant is emerging as potential cancer treatments that hold great promise in the area of clinical cancer research.
  • These targeting and stem cell-based therapies may offer the ultimate hope for treating and even curing the patients diagnosed with locally advanced cancers at high risk of recurrence, metastatic and/or relapsed cancers in the clinics.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Hematology Am Soc Hematol Educ Program. 2003;:82-101 [14633778.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Dec 9;100(25):15178-83 [14645703.001]
  • [Cites] Blood. 2004 Feb 1;103(3):1166-70 [14512297.001]
  • [Cites] Blood. 2004 Mar 15;103(6):2332-6 [14630803.001]
  • [Cites] Cancer Lett. 2004 Feb 20;204(2):213-24 [15013220.001]
  • [Cites] Blood Rev. 2004 Sep;18(3):167-79 [15183901.001]
  • [Cites] Eur J Cancer. 2004 Jul;40(10):1522-9 [15196536.001]
  • [Cites] Crit Rev Oncol Hematol. 2004 Jul;51(1):1-28 [15207251.001]
  • [Cites] Nat Immunol. 2004 Jul;5(7):738-43 [15170211.001]
  • [Cites] Transfusion. 2004 Jul;44(7):1087-97 [15225252.001]
  • [Cites] Panminerva Med. 2004 Mar;46(1):49-59 [15238881.001]
  • [Cites] Skin Pharmacol Physiol. 2004 Jul-Aug;17(4):153-66 [15258446.001]
  • [Cites] N Engl J Med. 2004 Aug 12;351(7):657-67 [15306667.001]
  • [Cites] N Engl J Med. 2004 Sep 2;351(10):998-1012 [15342808.001]
  • [Cites] Oncogene. 2004 Sep 20;23(43):7274-82 [15378087.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Sep 28;101(39):14228-33 [15381773.001]
  • [Cites] Am J Pathol. 2006 Dec;169(6):2223-35 [17148683.001]
  • [Cites] Expert Opin Biol Ther. 2007 Jan;7(1):41-51 [17150018.001]
  • [Cites] Nature. 2006 Dec 7;444(7120):756-60 [17051156.001]
  • [Cites] Neurobiol Dis. 2007 Feb;25(2):217-29 [17141509.001]
  • [Cites] Cancer Res. 2007 Feb 1;67(3):1030-7 [17283135.001]
  • [Cites] Cancer Res. 2007 Feb 1;67(3):1113-20 [17283145.001]
  • [Cites] Stem Cells. 2007 Feb;25(2):371-9 [17038675.001]
  • [Cites] J BUON. 2006 Oct-Dec;11(4):433-8 [17309174.001]
  • [Cites] Nature. 2007 Feb 22;445(7130):851-7 [17314971.001]
  • [Cites] Cancer Res. 2007 Mar 1;67(5):2187-96 [17332349.001]
  • [Cites] Best Pract Res Clin Haematol. 2007 Mar;20(1):57-65 [17336255.001]
  • [Cites] J Natl Compr Canc Netw. 2007 Feb;5(2):203-15 [17335689.001]
  • [Cites] Blood. 2007 Jun 1;109(11):4635-40 [17299092.001]
  • [Cites] Genes Dev. 2007 Jun 1;21(11):1382-95 [17510286.001]
  • [Cites] Pediatr Blood Cancer. 2007 Aug;49(2):196-8 [17417796.001]
  • [Cites] Mol Vis. 2007;13:823-32 [17615543.001]
  • [Cites] Carcinogenesis. 2007 Jul;28(7):1379-86 [17341655.001]
  • [Cites] Clin Exp Metastasis. 2007;24(5):353-62 [17487557.001]
  • [Cites] Clin Pharmacol Ther. 2007 Sep;82(3):252-64 [17671448.001]
  • [Cites] Stem Cells Dev. 2007 Aug;16(4):637-48 [17784837.001]
  • [Cites] Stem Cells. 2007 Sep;25(9):2302-11 [17569791.001]
  • [Cites] Ann Oncol. 2007 Oct;18(10):1605-19 [17355951.001]
  • [Cites] Carcinogenesis. 2007 Sep;28(9):2053-8 [17434930.001]
  • [Cites] Int J Cancer. 2007 Nov 15;121(10):2125-31 [17565741.001]
  • [Cites] Clin Exp Metastasis. 2007;24(7):485-93 [17653825.001]
  • [Cites] Pigment Cell Res. 2007 Dec;20(6):458-65 [17935489.001]
  • [Cites] Cancer Treat Rev. 2008 May;34(3):247-58 [18226859.001]
  • [Cites] Stem Cell Rev. 2008 Spring;4(1):27-49 [18288619.001]
  • [Cites] Blood. 2000 Feb 1;95(3):1007-13 [10648416.001]
  • [Cites] Blood. 2001 Aug 15;98(4):1166-73 [11493466.001]
  • [Cites] Lancet Oncol. 2002 Jan;3(1):35-43 [11905603.001]
  • [Cites] Nat Immunol. 2002 Jul;3(7):687-94 [12068293.001]
  • [Cites] Nat Rev Cancer. 2002 Jun;2(6):442-54 [12189386.001]
  • [Cites] Cancer Cell. 2002 Sep;2(3):175-8 [12242149.001]
  • [Cites] Cancer Res. 2002 Oct 15;62(20):5657-63 [12384520.001]
  • [Cites] Nat Rev Cancer. 2002 Nov;2(11):826-35 [12415253.001]
  • [Cites] Cancer Res. 2002 Dec 15;62(24):7170-4 [12499252.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Apr 1;100(7):3983-8 [12629218.001]
  • [Cites] Pathol Oncol Res. 2003;9(1):13-9 [12704441.001]
  • [Cites] Growth Factors. 2003 Mar;21(1):1-14 [12795332.001]
  • [Cites] Nat Rev Cancer. 2003 Sep;3(9):685-94 [12951587.001]
  • [Cites] Cell Mol Life Sci. 2005 Aug;62(16):1863-70 [16003493.001]
  • [Cites] Nat Rev Cancer. 2005 Sep;5(9):744-9 [16148886.001]
  • [Cites] Mini Rev Med Chem. 2005 Sep;5(9):805-24 [16178723.001]
  • [Cites] Ernst Schering Found Symp Proc. 2006;(5):155-79 [17939301.001]
  • [Cites] Oncologist. 2007 Oct;12(10):1237-46 [17962617.001]
  • [Cites] Front Biosci. 2008;13:1887-91 [17981676.001]
  • [Cites] J Cell Mol Med. 2007 Sep-Oct;11(5):981-1011 [17979879.001]
  • [Cites] Med Princ Pract. 2008;17(1):84-5 [18059108.001]
  • [Cites] Br J Hosp Med (Lond). 2007 Nov;68(11):589-93 [18087845.001]
  • [Cites] Invest Ophthalmol Vis Sci. 2008 Feb;49(2):636-43 [18235009.001]
  • [Cites] J Clin Oncol. 2008 Feb 1;26(4):626-32 [18235122.001]
  • [Cites] Nat Clin Pract Oncol. 2008 Feb;5(2):102-11 [18235442.001]
  • [Cites] Nat Rev Cancer. 2006 Jun;6(6):425-36 [16723989.001]
  • [Cites] Mol Cancer Ther. 2006 May;5(5):1299-308 [16731763.001]
  • [Cites] Eur J Cancer. 2006 Jun;42(9):1309-15 [16682183.001]
  • [Cites] Cancer Res. 2006 Jun 15;66(12):6063-71 [16778178.001]
  • [Cites] J Clin Oncol. 2006 Jun 20;24(18):2891-6 [16782928.001]
  • [Cites] J Cell Biochem. 2006 Jul 1;98(4):757-69 [16598744.001]
  • [Cites] Hepatology. 2006 Jul;44(1):240-51 [16799977.001]
  • [Cites] Curr Drug Targets. 2006 Jul;7(7):861-79 [16842217.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Jul 25;103(30):11154-9 [16849428.001]
  • [Cites] Cancer Res. 2004 Oct 1;64(19):7011-21 [15466194.001]
  • [Cites] Cancer Res. 2006 Aug 1;66(15):7445-52 [16885340.001]
  • [Cites] Leukemia. 2006 Sep;20(9):1533-8 [16871285.001]
  • [Cites] Cell Cycle. 2006 Aug;5(15):1597-601 [16880743.001]
  • [Cites] Pediatr Blood Cancer. 2006 Oct 15;47(5):560-6 [16395684.001]
  • [Cites] Leuk Lymphoma. 2006 Aug;47(8):1545-52 [16966265.001]
  • [Cites] Mol Cancer Res. 2006 Sep;4(9):607-19 [16966431.001]
  • [Cites] Bone Marrow Transplant. 2006 Oct;38(7):493-9 [16980997.001]
  • [Cites] Hum Mol Genet. 2006 Oct 15;15 Spec No 2:R210-9 [16987886.001]
  • [Cites] Ann Oncol. 2006 Nov;17(11):1620-4 [16600978.001]
  • [Cites] Stem Cells. 2006 Nov;24(11):2319-45 [16794264.001]
  • [Cites] Klin Padiatr. 2006 Nov-Dec;218(6):321-6 [17080334.001]
  • [Cites] Int J Cancer. 2007 Jan 1;120(1):160-9 [17013895.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Nov 7;103(45):16870-5 [17077147.001]
  • [Cites] Panminerva Med. 2006 Sep;48(3):165-74 [17122752.001]
  • [Cites] Hematology Am Soc Hematol Educ Program. 2006;:219-25 [17124064.001]
  • [Cites] J Cell Mol Med. 2006 Oct-Dec;10(4):857-65 [17125590.001]
  • [Cites] J Cell Mol Med. 2006 Oct-Dec;10(4):995-1013 [17125601.001]
  • [Cites] Clin Invest Med. 2006 Oct;29(5):301-11 [17144440.001]
  • [Cites] Exp Cell Res. 2006 Nov 15;312(19):3701-10 [17046749.001]
  • [Cites] Mol Vis. 2005;11:729-37 [16179903.001]
  • [Cites] Hematology. 2005 Oct;10(5):349-59 [16203604.001]
  • [Cites] Expert Rev Anticancer Ther. 2005 Oct;5(5):835-46 [16221053.001]
  • [Cites] Expert Rev Vaccines. 2005 Oct;4(5):699-710 [16221071.001]
  • [Cites] Cancer Cell. 2005 Oct;8(4):323-35 [16226707.001]
  • [Cites] Cancer Res. 2005 Oct 15;65(20):9328-37 [16230395.001]
  • [Cites] Chest. 2005 Oct;128(4):2268-73 [16236883.001]
  • [Cites] Pancreas. 2005 Nov;31(4):301-16 [16258363.001]
  • [Cites] Curr Opin Neurol. 2005 Dec;18(6):639-44 [16280674.001]
  • [Cites] Cancer Lett. 2005 Dec 18;230(2):199-210 [16297706.001]
  • [Cites] Leukemia. 2005 Dec;19(12):2304-12 [16193083.001]
  • [Cites] Cancer Res. 2005 Dec 1;65(23):10946-51 [16322242.001]
  • [Cites] Haematologica. 2007 Mar;92(3):323-31 [17339181.001]
  • [Cites] PLoS One. 2007;2(3):e293 [17356702.001]
  • [Cites] Br J Haematol. 2007 Apr;137(1):20-35 [17359369.001]
  • [Cites] Mol Cancer Ther. 2007 Mar;6(3):967-78 [17363490.001]
  • [Cites] Semin Cancer Biol. 2007 Jun;17(3):241-7 [16839774.001]
  • [Cites] Bone Marrow Transplant. 2007 Apr;39(7):397-400 [17322933.001]
  • [Cites] Cancer Metastasis Rev. 2007 Mar;26(1):203-14 [17273942.001]
  • [Cites] J Thorac Oncol. 2007 Apr;2(4):327-43 [17409807.001]
  • [Cites] Adv Cancer Res. 2007;97:25-60 [17419940.001]
  • [Cites] Exp Clin Endocrinol Diabetes. 2007 Mar;115(3):160-5 [17427103.001]
  • [Cites] Oncology. 2006;71(1-2):32-9 [17344669.001]
  • [Cites] Exp Gerontol. 2007 May;42(5):385-90 [17275237.001]
  • [Cites] Curr Eye Res. 2007 Mar;32(3):281-90 [17453948.001]
  • [Cites] Leukemia. 2007 May;21(5):926-35 [17330101.001]
  • [Cites] Nat Rev Drug Discov. 2006 Aug;5(8):649-59 [16883303.001]
  • [Cites] Leukemia. 2007 May;21(5):949-55 [17361218.001]
  • [Cites] Cancer Cell. 2007 May;11(5):421-9 [17482132.001]
  • [Cites] Crit Rev Oncol Hematol. 2007 Jun;62(3):214-26 [17368038.001]
  • [Cites] Philos Trans R Soc Lond B Biol Sci. 2007 Jun 29;362(1482):959-71 [17317642.001]
  • [Cites] Trends Mol Med. 2007 May;13(5):192-9 [17383232.001]
  • [Cites] Biochem Biophys Res Commun. 2007 Jun 15;357(4):1084-9 [17466949.001]
  • [Cites] Cancer Res. 2007 May 15;67(10):4807-15 [17510410.001]
  • [Cites] Cancer Res. 2007 May 15;67(10):4827-33 [17510412.001]
  • [Cites] J Cell Sci. 2007 Feb 1;120(Pt 3):468-77 [17227796.001]
  • [Cites] Nature. 2004 Oct 7;431(7009):707-12 [15361885.001]
  • [Cites] Nature. 1984 Feb 2-8;307(5950):471-3 [6694739.001]
  • [Cites] J Clin Oncol. 1998 Jan;16(1):165-72 [9440739.001]
  • [Cites] Nat Med. 1998 Sep;4(9):1038-45 [9734397.001]
  • [Cites] Nature. 2004 Nov 18;432(7015):324-31 [15549094.001]
  • [Cites] Nature. 2004 Nov 18;432(7015):396-401 [15549107.001]
  • [Cites] Springer Semin Immunopathol. 2004 Nov;26(1-2):95-108 [15378271.001]
  • [Cites] Oncogene. 2004 Dec 16;23(58):9392-400 [15558011.001]
  • [Cites] J Clin Oncol. 2005 Jan 10;23(2):293-300 [15637392.001]
  • [Cites] Carcinogenesis. 2005 Feb;26(2):495-502 [15513931.001]
  • [Cites] Cell Cycle. 2004 Dec;3(12):1502-5 [15611623.001]
  • [Cites] Nat Rev Cancer. 2005 Feb;5(2):91-101 [15685194.001]
  • [Cites] J Neurooncol. 2005 Jan;71(1):33-8 [15719272.001]
  • [Cites] Nat Rev Cancer. 2005 Apr;5(4):275-84 [15803154.001]
  • [Cites] Bone Marrow Transplant. 2005 Apr;35(8):763-6 [15750608.001]
  • [Cites] Med Hypotheses. 2005;64(6):1182-7 [15823713.001]
  • [Cites] Cancer Res. 2005 Apr 15;65(8):3025-9 [15833827.001]
  • [Cites] Am J Clin Oncol. 2005 Jun;28(3):281-8 [15923802.001]
  • [Cites] Cancer Res. 2005 Jun 1;65(11):4490-5 [15930263.001]
  • [Cites] Breast Cancer Res. 2005;7(3):86-95 [15987436.001]
  • [Cites] J Pediatr Surg. 2005 Jun;40(6):936-41; discussion 941 [15991174.001]
  • [Cites] Cancer Res. 2005 Jul 1;65(13):5506-11 [15994920.001]
  • [Cites] Cancer Res. 2005 Jul 15;65(14):6207-19 [16024622.001]
  • [Cites] Neoplasia. 2005 Jun;7(6):623-9 [16036113.001]
  • [Cites] Lancet. 2005 Jul 23-29;366(9482):318-20 [16039336.001]
  • [Cites] Br J Haematol. 2005 Aug;130(3):373-81 [16042686.001]
  • [Cites] Cancer Cell. 2005 Aug;8(2):119-30 [16098465.001]
  • [Cites] N Engl J Med. 2005 Aug 25;353(8):811-22 [16120861.001]
  • [Cites] Cancer Cell. 2008 Feb;13(2):153-66 [18242515.001]
  • [Cites] Cell Death Differ. 2008 Mar;15(3):504-14 [18049477.001]
  • [Cites] J Cell Physiol. 2008 May;215(2):287-91 [18205182.001]
  • [Cites] BMC Cancer. 2008;8:48 [18261235.001]
  • [Cites] Growth Factors. 2007 Dec;25(6):400-16 [18365871.001]
  • [Cites] Cell Stem Cell. 2007 Sep 13;1(3):313-23 [18371365.001]
  • [Cites] Endocr Rev. 2008 Apr;29(2):234-52 [18292464.001]
  • [Cites] Clin Pharmacol Ther. 2008 May;83(5):673-91 [17786164.001]
  • [Cites] Breast Cancer Res. 2008;10(1):R10 [18241344.001]
  • [Cites] Semin Oncol. 2005 Dec;32(6 Suppl 9):S78-81 [16399438.001]
  • [Cites] J Invest Dermatol. 2006 Jan;126(1):142-53 [16417230.001]
  • [Cites] J Exp Med. 2006 Jan 23;203(1):73-85 [16380511.001]
  • [Cites] Int J Cancer. 2006 Feb 15;118(4):1022-31 [16108016.001]
  • [Cites] Cancer. 2006 Feb 15;106(4):859-66 [16419074.001]
  • [Cites] Nat Rev Drug Discov. 2006 Feb;5(2):147-59 [16424916.001]
  • [Cites] Cell Cycle. 2006 Feb;5(4):452-6 [16479164.001]
  • [Cites] Oncogene. 2006 Mar 16;25(12):1696-708 [16449977.001]
  • [Cites] J Pediatr Surg. 2006 Apr;41(4):624-32; discussion 624-32 [16567167.001]
  • [Cites] Stem Cells. 2006 Mar;24(3):506-13 [16239320.001]
  • [Cites] J Clin Oncol. 2006 Apr 20;24(12):1924-31 [16567768.001]
  • [Cites] Hum Cell. 2006 Feb;19(1):24-9 [16643604.001]
  • [Cites] Cancer Res. 2006 May 1;66(9):4553-7 [16651403.001]
  • [Cites] Blood. 2006 Jun 1;107(11):4532-9 [16469872.001]
  • [Cites] Leuk Lymphoma. 2006 Jan;47(1):1-7 [16321820.001]
  • [Cites] Neoplasia. 2005 Nov;7(11):967-76 [16331882.001]
  • [Cites] Nature. 2005 Dec 8;438(7069):820-7 [16341007.001]
  • [Cites] Cancer Res. 2005 Dec 15;65(24):11459-68 [16357154.001]
  • [Cites] Carcinogenesis. 2006 Jan;27(1):1-22 [16195239.001]
  • [Cites] Nat Rev Neurosci. 2006 Jan;7(1):75-84 [16371952.001]
  • [Cites] Adv Cancer Res. 2007;96:23-50 [17161675.001]
  • [Cites] Mol Cancer. 2006;5:67 [17140455.001]
  • [Cites] Mod Pathol. 2007 Jan;20(1):102-7 [17143262.001]
  • [Cites] Semin Diagn Pathol. 2006 May;23(2):63-9 [17193819.001]
  • [Cites] PLoS Med. 2006 Dec;3(12):e482 [17194186.001]
  • [Cites] Nature. 2007 Jan 4;445(7123):111-5 [17122771.001]
  • [Cites] PLoS One. 2006;1:e23 [17183650.001]
  • [Cites] Pediatr Blood Cancer. 2007 Mar;48(3):349-53 [16302216.001]
  • [Cites] Annu Rev Med. 2007;58:267-84 [17002552.001]
  • [Cites] Cancer Cell. 2007 Jan;11(1):69-82 [17222791.001]
  • [Cites] Expert Opin Biol Ther. 2006 Dec;6(12):1255-62 [17223735.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 Jan 16;104(3):973-8 [17210912.001]
  • [Cites] CA Cancer J Clin. 2007 Jan-Feb;57(1):43-66 [17237035.001]
  • [Cites] Curr Biol. 2007 Jan 23;17(2):165-72 [17196391.001]
  • [Cites] Biol Blood Marrow Transplant. 2007 Feb;13(2):235-44 [17241929.001]
  • [Cites] Neurosurg Clin N Am. 2007 Jan;18(1):59-69, viii-ix [17244554.001]
  • [Cites] Neurosurg Clin N Am. 2007 Jan;18(1):71-80, ix [17244555.001]
  • (PMID = 18427384.001).
  • [ISSN] 0031-0808
  • [Journal-full-title] Panminerva medica
  • [ISO-abbreviation] Panminerva Med
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA078590; United States / NCI NIH HHS / CA / U01 CA111294; United States / NCI NIH HHS / CA / CA111294; United States / NCI NIH HHS / CA / CA78590
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, Non-P.H.S.; Review
  • [Publication-country] Italy
  • [Number-of-references] 210
  • [Other-IDs] NLM/ NIHMS526856; NLM/ PMC3828640
  •  go-up   go-down


20. Koeller KK, Rushing EJ: From the archives of the AFIP: medulloblastoma: a comprehensive review with radiologic-pathologic correlation. Radiographics; 2003 Nov-Dec;23(6):1613-37
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Medulloblastoma is the most common pediatric central nervous system malignancy and the most common primary tumor of the posterior fossa in children.
  • This highly malignant neoplasm occurs more frequently in males and usually before 10 years of age.
  • Clinical symptoms and signs are generally brief, typically less than 3 months in duration, and reflect the strong predilection of this tumor to arise within the cerebellum, most often in the vermis.
  • Surgical resection, radiation therapy, and chemotherapy have substantially lowered the mortality associated with this tumor, with 5-year survival rates now commonly well above 50%.
  • Still, both dissemination at the time of diagnosis and recurrence remain obstacles in achieving a cure.
  • The tumor has characteristic hyperattenuation on unenhanced computed tomographic scans that reflects the high nuclear-cytoplasmic ratio seen at histologic analysis.
  • The tumor typically appears heterogeneous on images, findings that are related to cyst formation, hemorrhage, and calcification and that are even more pronounced with magnetic resonance (MR) imaging.
  • Evidence of leptomeningeal metastatic spread is present in 33% of all cases at the time of diagnosis and is well evaluated with contrast-enhanced MR imaging of the brain and the spine.
  • With continued research, treatment of these common neoplasms should improve, perhaps even achieving a cure in the future.
  • [MeSH-major] Cerebellar Neoplasms / radiography. Magnetic Resonance Imaging. Medulloblastoma / radiography. Tomography, X-Ray Computed
  • [MeSH-minor] Adolescent. Adult. Aged. Child. Child, Preschool. Female. Humans. Infant. Male. Meninges / pathology. Middle Aged. Neoplasm Invasiveness. Prognosis. Survival Rate

  • Genetic Alliance. consumer health - Medulloblastoma.
  • MedlinePlus Health Information. consumer health - CT Scans.
  • MedlinePlus Health Information. consumer health - MRI Scans.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14615567.001).
  • [ISSN] 1527-1323
  • [Journal-full-title] Radiographics : a review publication of the Radiological Society of North America, Inc
  • [ISO-abbreviation] Radiographics
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 102
  •  go-up   go-down


21. Rocha LA, Rizo VH, Romañach MJ, de Almeida OP, Vargas PA: Oral metastasis of alveolar soft-part sarcoma: a case report and review of literature. Oral Surg Oral Med Oral Pathol Oral Radiol Endod; 2010 Apr;109(4):587-93
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Oral metastasis of alveolar soft-part sarcoma: a case report and review of literature.
  • Alveolar soft-part sarcoma (ASPS) is a rare malignant neoplasm with uncertain histogenesis and with a distinctive morphology.
  • A 27-year-old male patient, who was under chemotherapy treatment for ASPS of the thigh, presented in our dental clinic with a painless and pedunculated nodule on the right tuber maxillae.
  • An incisional biopsy was performed and the diagnosis of metastatic ASPS was made.
  • Histologically, the tumor was characterized by a proliferation of polyhedral cells in pseudoalveolar pattern.
  • Tumor cells were large, showing granular cytoplasm, periodic acid-Schiff positive diastase-resistant intracytoplasmic material, and vesicular nuclei with prominent nucleoli.
  • Unfortunately, the patient died 2 months after the diagnosis of the oral metastasis.
  • Metastases of ASPS to the mouth are very rare and indicate a poor prognosis.
  • [MeSH-major] Gingival Neoplasms / secondary. Maxilla / pathology. Sarcoma, Alveolar Soft Part / secondary
  • [MeSH-minor] Adult. Brain Neoplasms / secondary. Cell Nucleolus / ultrastructure. Cell Nucleus / ultrastructure. Cytoplasm / ultrastructure. Diagnosis, Differential. Fatal Outcome. Gingival Diseases / diagnosis. Granuloma, Giant Cell / diagnosis. Granuloma, Pyogenic / diagnosis. Humans. Male. Muscle Neoplasms / pathology. Thigh / pathology

  • Genetic Alliance. consumer health - Alveolar Soft Part Sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 Mosby, Inc. All rights reserved.
  • (PMID = 20303057.001).
  • [ISSN] 1528-395X
  • [Journal-full-title] Oral surgery, oral medicine, oral pathology, oral radiology, and endodontics
  • [ISO-abbreviation] Oral Surg Oral Med Oral Pathol Oral Radiol Endod
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


22. Vestermark LW, Larsen S, Lindeløv B, Bastholt L: A phase II study of thalidomide in patients with brain metastases from malignant melanoma. Acta Oncol; 2008;47(8):1526-30
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A phase II study of thalidomide in patients with brain metastases from malignant melanoma.
  • INTRODUCTION: Brain metastases develop in nearly half of the patients with advanced melanoma and in 15 to 20% of these patients CNS is the first site of relapse.
  • Results obtained in prior trials indicate that Thalidomide acts as a cytostatic agent in metastatic melanoma.
  • We evaluated single agent antitumour activity and toxicity of Thalidomide in a phase II setting in patients with brain metastases associated with metastatic melanoma.
  • MATERIAL AND METHODS: Patients with measurable metastatic melanoma in progression and with PS < or = 2 were enrolled in the study.
  • Secondary objectives were to estimate time to progression, overall survival and to evaluate tolerability of the regimen.
  • None of the patients obtained a response in brain metastases.
  • Median time to progression and overall survival time was 1.7 and 3.1 months, respectively.
  • CONCLUSION: There were no objective responses in the brain but single agent Thalidomide has some activity in melanoma patients with brain metastases.
  • [MeSH-major] Angiogenesis Inhibitors / therapeutic use. Brain Neoplasms / drug therapy. Melanoma / drug therapy. Skin Neoplasms / drug therapy. Thalidomide / therapeutic use
  • [MeSH-minor] Adult. Aged. Disease Progression. Disease-Free Survival. Female. Humans. Male. Middle Aged. Neoplasm Staging. Survival Rate. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Melanoma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. THALIDOMIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18607876.001).
  • [ISSN] 1651-226X
  • [Journal-full-title] Acta oncologica (Stockholm, Sweden)
  • [ISO-abbreviation] Acta Oncol
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article
  • [Publication-country] Norway
  • [Chemical-registry-number] 0 / Angiogenesis Inhibitors; 4Z8R6ORS6L / Thalidomide
  •  go-up   go-down


23. Piscitelli D, Sanguedolce F, Mattioli E, Parisi G, Fiore MG, Resta L: [Unusual presentation of metastatic osteosarcoma as a giant duodenal polyp. A case report]. Pathologica; 2005 Apr;97(2):88-91
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Unusual presentation of metastatic osteosarcoma as a giant duodenal polyp. A case report].
  • INTRODUCTION: Osteosarcoma is a malignant bone neoplasm with an usually high metastatic potential.
  • Besides the common metastatic sites such as lungs, bone, and pleura, metastases to unusual sites such as liver, brain and regional lymph nodes have also been reported with increasing frequency; among them, gastrointestinal metastases represent an extraordinarily rare event in the natural history of this neoplasia.
  • MATERIALS AND METHODS: We describe a case of a 27 year old man, who was diagnosed with a grade IV osteoblastic osteosarcoma of the left tibia and submitted to 5 courses of pre-surgical chemotherapy; later he underwent tibial resection with implantation of a prosthesis, followed by 2 further courses of adjuvant chemotherapy.
  • RESULTS: Microscopically, the tumor mass showed a mostly fasciculated architecture, composed of spindle and epithelioid cells in a scarce fibromyxoid stroma, featuring large areas of coagulative necrosis and small foci of sclerohyalinosis.
  • Tumor cells featured large vesciculous nuclei, with a few prominent nucleoli; no foci of osteoid matrix were detectable.
  • Due to alteration of the natural history of the tumor induced by multiagent chemotherapy, the rate of metastases of osteosarcoma to unusual sites has been increasing.
  • We report the 9th case of a gastrointestinal metastasis of osteosarcoma reported thus far, and only the second one arising in the duodenum.
  • Both the histological features and the immunohistochemical findings were not suggestive for osteosarcoma metastases because the tumor appeared dedifferentiated; in our case the combination of electron microscopy and clinical history played a pivotal role to establish the final diagnosis.
  • [MeSH-major] Bone Neoplasms / pathology. Duodenal Neoplasms / pathology. Duodenal Neoplasms / secondary. Osteosarcoma / secondary. Tibia
  • [MeSH-minor] Adult. Duodenal Diseases / etiology. Duodenal Diseases / pathology. Humans. Intestinal Polyps / etiology. Intestinal Polyps / pathology. Male

  • Genetic Alliance. consumer health - Osteosarcoma.
  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • MedlinePlus Health Information. consumer health - Intestinal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16032954.001).
  • [ISSN] 0031-2983
  • [Journal-full-title] Pathologica
  • [ISO-abbreviation] Pathologica
  • [Language] ita
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


24. Hentschel S, Toyota B: Intracranial malignant glioma presenting as subarachnoid hemorrhage. Can J Neurol Sci; 2003 Feb;30(1):63-6
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intracranial malignant glioma presenting as subarachnoid hemorrhage.
  • Cerebral neoplasms are clearly on this list but are most commonly meningiomas or metastatic lesions.
  • This article details a case of a neoplasm that presented exclusively with SAH.
  • INTERVENTION: Craniotomy and resection of the lesion established a diagnosis of a malignant oligodendroglioma.
  • [MeSH-major] Brain Neoplasms / diagnosis. Oligodendroglioma / diagnosis. Subarachnoid Hemorrhage / etiology
  • [MeSH-minor] Adult. Anticonvulsants / therapeutic use. Cerebral Angiography. Humans. Magnetic Resonance Imaging. Male. Neurosurgical Procedures. Seizures / drug therapy. Seizures / etiology

  • Genetic Alliance. consumer health - Glioma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12619787.001).
  • [ISSN] 0317-1671
  • [Journal-full-title] The Canadian journal of neurological sciences. Le journal canadien des sciences neurologiques
  • [ISO-abbreviation] Can J Neurol Sci
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Canada
  • [Chemical-registry-number] 0 / Anticonvulsants
  •  go-up   go-down


25. Mimeault M, Hauke R, Mehta PP, Batra SK: Recent advances in cancer stem/progenitor cell research: therapeutic implications for overcoming resistance to the most aggressive cancers. J Cell Mol Med; 2007 Sep-Oct;11(5):981-1011
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Recent advances in cancer stem/progenitor cell research: therapeutic implications for overcoming resistance to the most aggressive cancers.
  • Overcoming intrinsic and acquired resistance of cancer stem/progenitor cells to current clinical treatments represents a major challenge in treating and curing the most aggressive and metastatic cancers.
  • This review summarizes recent advances in our understanding of the cellular origin and molecular mechanisms at the basis of cancer initiation and progression as well as the heterogeneity of cancers arising from the malignant transformation of adult stem/progenitor cells.
  • We describe the critical functions provided by several growth factor cascades, including epidermal growth factor receptor (EGFR), platelet-derived growth factor receptor (PDGFR), stem cell factor (SCF) receptor (KIT), hedgehog and Wnt/beta-catenin signalling pathways that are frequently activated in cancer progenitor cells and are involved in their sustained growth, survival, invasion and drug resistance.
  • Of therapeutic interest, we also discuss recent progress in the development of new drug combinations to treat the highly aggressive and metastatic cancers including refractory/relapsed leukaemias, melanoma and head and neck, brain, lung, breast, ovary, prostate, pancreas and gastrointestinal cancers which remain incurable in the clinics.
  • The emphasis is on new therapeutic strategies consisting of molecular targeting of distinct oncogenic signalling elements activated in the cancer progenitor cells and their local microenvironment during cancer progression.
  • These new targeted therapies should improve the efficacy of current therapeutic treatments against aggressive cancers, and thereby preventing disease relapse and enhancing patient survival.

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17979879.001).
  • [ISSN] 1582-1838
  • [Journal-full-title] Journal of cellular and molecular medicine
  • [ISO-abbreviation] J. Cell. Mol. Med.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / U01 CA111294; United States / NCI NIH HHS / CA / CA72712; United States / NCI NIH HHS / CA / R01 CA078590; United States / NCI NIH HHS / CA / CA78590; United States / NCI NIH HHS / CA / P50 CA072712; United States / NCI NIH HHS / CA / CA111294
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, Non-P.H.S.; Review
  • [Publication-country] England
  • [Number-of-references] 242
  • [Other-IDs] NLM/ PMC4401269
  •  go-up   go-down


26. Clark JI, Moon J, Hutchins LF, Sosman JA, Kast WM, Da Silva DM, Liu PY, Thompson JA, Flaherty LE, Sondak VK: Phase 2 trial of combination thalidomide plus temozolomide in patients with metastatic malignant melanoma: Southwest Oncology Group S0508. Cancer; 2010 Jan 15;116(2):424-31
Hazardous Substances Data Bank. THALIDOMIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase 2 trial of combination thalidomide plus temozolomide in patients with metastatic malignant melanoma: Southwest Oncology Group S0508.
  • We conducted a multicenter phase 2 trial to better define the clinical efficacy of thalidomide and temozolomide and the immune modulatory effects of thalidomide, when combined with temozolomide, in patients with metastatic melanoma.
  • METHODS: Patients must have had stage IV cutaneous melanoma, no active brain metastases, Zubrod PS 0-1, up to 1 prior systemic therapy excluding thalidomide, temozolomide, or dacarbazine, adequate organ function, and given informed consent.
  • Secondary endpoints included overall survival (OS), RR, toxicities, and assessment of relationships between biomarkers and clinical outcomes.
  • RESULTS: Sixty-four patients were enrolled; 2 refused treatment.
  • One treatment-related death occurred from myocardial infarction; 3 other grade 4 events occurred, including pulmonary embolism, neutropenia, and central nervous system (CNS) ischemia.

  • MedlinePlus Health Information. consumer health - Melanoma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. DACARBAZINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 1999 Jul;17(7):2105-16 [10561265.001]
  • [Cites] J Clin Oncol. 2008 Dec 10;26(35):5748-54 [19001327.001]
  • [Cites] J Clin Oncol. 2000 Jan;18(1):158-66 [10623706.001]
  • [Cites] Br J Cancer. 2000 Feb;82(4):812-7 [10732751.001]
  • [Cites] Am J Med. 2000 Apr 15;108(6):487-95 [10781782.001]
  • [Cites] Antimicrob Agents Chemother. 2000 Sep;44(9):2286-90 [10952569.001]
  • [Cites] Oncology (Williston Park). 2001 Jul;15(7):867-74; discussion 877-9 [11499688.001]
  • [Cites] N Engl J Med. 2001 Oct 18;345(16):1214-5 [11642248.001]
  • [Cites] Blood. 2001 Nov 1;98(9):2736-44 [11675346.001]
  • [Cites] J Clin Oncol. 2002 Jun 1;20(11):2610-5 [12039921.001]
  • [Cites] Nat Rev Immunol. 2002 Jun;2(6):389-400 [12093005.001]
  • [Cites] J Exp Med. 2002 Aug 5;196(3):379-87 [12163566.001]
  • [Cites] Nature. 2002 Dec 5;420(6915):502-7 [12466842.001]
  • [Cites] Nat Rev Immunol. 2003 Mar;3(3):189-98 [12658267.001]
  • [Cites] J Clin Oncol. 2003 Jul 1;21(13):2551-7 [12829675.001]
  • [Cites] Clin Cancer Res. 2003 Jul;9(7):2551-9 [12855630.001]
  • [Cites] J Clin Oncol. 2003 Sep 1;21(17):3351-6 [12947072.001]
  • [Cites] Clin Exp Immunol. 1995 Feb;99(2):160-7 [7851006.001]
  • [Cites] J Exp Med. 1998 Jun 1;187(11):1885-92 [9607928.001]
  • [Cites] J Immunol. 1999 Jul 1;163(1):380-6 [10384139.001]
  • [Cites] Melanoma Res. 2004 Dec;14(6):527-31 [15577325.001]
  • [Cites] Methods Mol Biol. 2005;302:237-52 [15937356.001]
  • [Cites] Clin Cancer Res. 2007 Apr 15;13(8):2385-91 [17438097.001]
  • [Cites] J Clin Oncol. 2008 Feb 1;26(4):527-34 [18235113.001]
  • [Cites] Proc Natl Acad Sci U S A. 2008 Sep 2;105(35):12643-4 [18753635.001]
  • [Cites] J Clin Oncol. 1999 Sep;17(9):2745-51 [10561349.001]
  • (PMID = 19918923.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / N01 CA004919; United States / NCI NIH HHS / CA / CA37981; United States / NCI NIH HHS / CA / CA58416; United States / NCI NIH HHS / CA / N01 CA035176; United States / NCI NIH HHS / CA / CA45560; United States / NCI NIH HHS / CA / U10 CA032102-30; United States / NCI NIH HHS / CA / CA35178; United States / NCI NIH HHS / CA / CA45807; United States / NCI NIH HHS / CA / CA35261; United States / NCI NIH HHS / CA / U10 CA004919; United States / NCI NIH HHS / CA / N01 CA035431; United States / NCI NIH HHS / CA / CA22433; United States / NCI NIH HHS / CA / CA35431; United States / NCI NIH HHS / CA / U10 CA045560; United States / NCI NIH HHS / CA / CA20319; United States / NCI NIH HHS / CA / N01 CA032102; United States / NCI NIH HHS / CA / CA76426; United States / NCI NIH HHS / CA / U10 CA045808; United States / NCI NIH HHS / CA / N01 CA045807; United States / NCI NIH HHS / CA / CA45808; United States / NCI NIH HHS / CA / U10 CA074647; United States / NCI NIH HHS / CA / CA11083; United States / NCI NIH HHS / CA / CA58861; United States / NCI NIH HHS / CA / K24 CA097588; United States / NCI NIH HHS / CA / CA46282; United States / NCI NIH HHS / CA / U10 CA035261; United States / NCI NIH HHS / CA / U10 CA035178; United States / NCI NIH HHS / CA / U10 CA045461; United States / NCI NIH HHS / CA / U10 CA032102; United States / NCI NIH HHS / CA / U10 CA046282; United States / NCI NIH HHS / CA / CA32102; United States / NCI NIH HHS / CA / CA38926; United States / NCI NIH HHS / CA / N01 CA035178; United States / NCI NIH HHS / CA / N01 CA038926; United States / NCI NIH HHS / CA / CA032102-30; United States / NCI NIH HHS / CA / CA45461; United States / NCI NIH HHS / CA / U10 CA067575; United States / NCI NIH HHS / CA / CA74647; United States / NCI NIH HHS / CA / U10 CA020319; United States / NCI NIH HHS / CA / U10 CA038926; United States / NCI NIH HHS / CA / CA35176; United States / NCI NIH HHS / CA / U10 CA035431; United States / NCI NIH HHS / CA / U10 CA011083; United States / NCI NIH HHS / CA / N01 CA067575; United States / NCI NIH HHS / CA / CA04919; United States / NCI NIH HHS / CA / U10 CA035176; United States / NCI NIH HHS / CA / CA67575; United States / NCI NIH HHS / CA / U10 CA045807; United States / NCI NIH HHS / CA / N01 CA045560
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 4Z8R6ORS6L / Thalidomide; 7GR28W0FJI / Dacarbazine; 85622-93-1 / temozolomide
  • [Other-IDs] NLM/ NIHMS151995; NLM/ PMC2811758
  •  go-up   go-down


27. Andersson R, Ake Hofer P, Riklund-Ahlström K, Henriksson R: Effects of interferon-alpha, verapamil and dacarbazine in the treatment of advanced malignant melanoma. Melanoma Res; 2003 Feb;13(1):87-91
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Effects of interferon-alpha, verapamil and dacarbazine in the treatment of advanced malignant melanoma.
  • Treatment of patients with metastatic melanoma with either dacarbazine (DTIC) or interferon-alpha (IFNalpha) as single drugs, or in combination, results in a response rate of approximately 15-20%.
  • This study evaluated the activity and toxicity following treatment with a combination of DTIC, IFNalpha2b and verapamil (VPL).
  • Thirty patients with disseminated metastatic melanoma received DTIC 250 mg/m(2) on days 1-5 of a 4 week schedule, IFNalpha2b 3 MIU on days 1-5 each week, and VPL 80 mg three times a day throughout the cycle, until either disease progression or serious toxicity was observed.
  • The fourth CR patient relapsed and died with progressive brain metastases after 8 months.
  • Despite one toxic death, these results suggest that this treatment regimen is well tolerated and seems to be more effective than DTIC alone in a subset of patients.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Melanoma / drug therapy. Skin Neoplasms / drug therapy. Uveal Neoplasms / drug therapy
  • [MeSH-minor] Adult. Aged. Calcium Channel Blockers / administration & dosage. Calcium Channel Blockers / therapeutic use. Dacarbazine / administration & dosage. Female. Humans. Interferon-alpha / administration & dosage. Male. Maximum Tolerated Dose. Middle Aged. Neoplasm Staging. Recombinant Proteins. Remission Induction. Survival Rate. Treatment Outcome. Verapamil / administration & dosage. Verapamil / therapeutic use

  • MedlinePlus Health Information. consumer health - Melanoma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. VERAPAMIL HYDROCHLORIDE .
  • Hazardous Substances Data Bank. DACARBAZINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12569290.001).
  • [ISSN] 0960-8931
  • [Journal-full-title] Melanoma research
  • [ISO-abbreviation] Melanoma Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Calcium Channel Blockers; 0 / Interferon-alpha; 0 / Recombinant Proteins; 7GR28W0FJI / Dacarbazine; 99210-65-8 / interferon alfa-2b; CJ0O37KU29 / Verapamil
  •  go-up   go-down


28. Tamaskar I, Mekhail T, Dreicer R, Olencki T, Roman S, Elson P, Bukowski RM: Phase I trial of weekly docetaxel and daily temozolomide in patients with metastatic disease. Invest New Drugs; 2008 Dec;26(6):553-9
Hazardous Substances Data Bank. DACARBAZINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase I trial of weekly docetaxel and daily temozolomide in patients with metastatic disease.
  • Temozolomide is an alkylating agent which crosses the blood brain barrier and has demonstrated antitumor activity against a broad range of tumor types, including malignant glioma, melanoma, non small cell lung cancer and carcinoma of the ovary and colon.
  • A Phase I trial was conducted to determine the toxicity of this combination in refractory solid tumor patients.
  • METHODS: Twenty five patients with metastatic cancers were enrolled in a Phase I dose escalation trial.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Neoplasms / drug therapy
  • [MeSH-minor] Administration, Oral. Adult. Aged. Dacarbazine / administration & dosage. Dacarbazine / analogs & derivatives. Dose-Response Relationship, Drug. Female. Humans. Infusions, Intravenous. Male. Maximum Tolerated Dose. Middle Aged. Neoplasm Metastasis. Survival Rate. Taxoids / administration & dosage

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. DOCETAXEL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Semin Oncol. 1998 Oct;25(5 Suppl 12):32-4 [9865710.001]
  • [Cites] J Clin Oncol. 2007 Apr 10;25(11):1377-82 [17416857.001]
  • [Cites] Cancer Treat Rev. 1997 Jan;23 (1):35-61 [9189180.001]
  • [Cites] Invest New Drugs. 1994;12(3):169-82 [7896535.001]
  • [Cites] Gynecol Oncol. 2002 Oct;87(1):98-103 [12468349.001]
  • [Cites] Clin Lung Cancer. 2002 May;3(4):254-8 [14662033.001]
  • [Cites] Cancer Res. 1991 Sep 15;51(18):4845-52 [1680023.001]
  • [Cites] Br J Cancer. 1992 Feb;65(2):287-91 [1739631.001]
  • [Cites] J Clin Oncol. 2000 May;18(10):2095-103 [10811675.001]
  • [Cites] J Clin Oncol. 1999 Sep;17 (9):2762-71 [10561351.001]
  • [Cites] Cancer. 2008 Apr 1;112(7):1455-61 [18300256.001]
  • [Cites] J Clin Oncol. 2005 Nov 20;23(33):8389-95 [16293869.001]
  • [Cites] Ann Oncol. 2005 Jan;16(1):90-6 [15598944.001]
  • [Cites] Cancer Res. 1998 Oct 1 ;58(19):4363-7 [9766665.001]
  • [Cites] Clin Cancer Res. 1999 Feb;5(2):309-17 [10037179.001]
  • [Cites] N Engl J Med. 1995 Apr 13;332(15):1004-14 [7885406.001]
  • [Cites] J Neurooncol. 2003 Feb;61(3):203-7 [12675312.001]
  • [Cites] Cancer Res. 1987 Nov 15;47(22):5846-52 [3664486.001]
  • [Cites] J Clin Oncol. 1995 Apr;13(4):910-3 [7707118.001]
  • [Cites] J Clin Oncol. 2002 Jan 15;20(2):420-5 [11786569.001]
  • [Cites] Br J Cancer. 1999 Nov;81(6):1022-30 [10576660.001]
  • [Cites] Br J Cancer. 2004 Dec 13;91(12):1996-2004 [15558071.001]
  • [Cites] J Clin Oncol. 2000 Jan;18(1):158-66 [10623706.001]
  • [Cites] Anticancer Drugs. 1997 Jan;8(1):92-7 [9147618.001]
  • [Cites] Clin Cancer Res. 1997 Jul;3(7):1093-100 [9815788.001]
  • [Cites] Br J Cancer. 2000 Sep;83(5):588-93 [10944597.001]
  • [Cites] J Neurooncol. 2005 Jan;71(1):61-5 [15719277.001]
  • [Cites] Eur J Cancer. 2000 Apr;36(6):742-7 [10762746.001]
  • [Cites] J Clin Oncol. 2000 Mar;18(6):1212-9 [10715290.001]
  • (PMID = 18626572.001).
  • [ISSN] 0167-6997
  • [Journal-full-title] Investigational new drugs
  • [ISO-abbreviation] Invest New Drugs
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase I; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Taxoids; 15H5577CQD / docetaxel; 7GR28W0FJI / Dacarbazine; YF1K15M17Y / temozolomide
  •  go-up   go-down


29. Okaji Y, Tsuno NH, Tanaka M, Yoneyama S, Matsuhashi M, Kitayama J, Saito S, Nagura Y, Tsuchiya T, Yamada J, Tanaka J, Yoshikawa N, Nishikawa T, Shuno Y, Todo T, Saito N, Takahashi K, Nagawa H: Pilot study of anti-angiogenic vaccine using fixed whole endothelium in patients with progressive malignancy after failure of conventional therapy. Eur J Cancer; 2008 Feb;44(3):383-90
MedlinePlus Health Information. consumer health - Colorectal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pilot study of anti-angiogenic vaccine using fixed whole endothelium in patients with progressive malignancy after failure of conventional therapy.
  • Six patients with recurrent malignant brain tumours and three patients with metastatic colorectal cancer received intradermal injections of 5x10(7) HUVECs/dose (in total 230 vaccinations).
  • Gadolinium-contrasted MRI showed partial or complete tumour responses in three malignant brain tumour patients.
  • [MeSH-major] Brain Neoplasms / prevention & control. Cancer Vaccines / administration & dosage. Colorectal Neoplasms / prevention & control. Endothelium, Vascular / immunology. Neovascularization, Pathologic / prevention & control. Umbilical Veins / immunology
  • [MeSH-minor] Adult. Aged. Cytotoxicity, Immunologic / drug effects. Cytotoxicity, Immunologic / immunology. Dendritic Cells / immunology. Enzyme-Linked Immunosorbent Assay. Female. Humans. Immunity, Cellular. Interferon-gamma / secretion. Male. Middle Aged. Neoplasm Metastasis / prevention & control. Neoplasm Recurrence, Local / prevention & control. Pilot Projects. T-Lymphocytes, Cytotoxic / immunology. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18060766.001).
  • [ISSN] 0959-8049
  • [Journal-full-title] European journal of cancer (Oxford, England : 1990)
  • [ISO-abbreviation] Eur. J. Cancer
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase I; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Cancer Vaccines; 82115-62-6 / Interferon-gamma
  •  go-up   go-down






Advertisement